Pixium Vision organize an open day
for investors on October 13thth 2022 out 17 o’clock
Registration required – Limited availability
Paris, France, September 21, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemonic: ALPIX), a bioelectronics company developing innovative bionic vision systems to help patients who have lost their sight to live more independently, announces today that it will host an open house for investors on Thursday, October 13thth2022.
The event, taking place from 17:00 to 19:00 CET, will be held in French and will feature an introduction by Lloyd Diamond, Chief Executive Officer, and Brian Burg, Director of R&D, on Pixium Vision and its upcoming Prima System bionic vision system clinical and developmental milestones and an overview of the dry age-related macular degeneration (AMD) disease and market landscape. There will be a guided tour of the Pixium Vision labs including a technology demonstration. The event will end with a drinks reception offering the opportunity to speak directly with the Pixium Vision team and use virtual reality to better understand the Prima system.
The Prima system, which has the potential to significantly improve the lives of patients with dry AMD,
is being investigated in the pivotal PRIMAvera study, which aims to confirm its safety and benefit, and is the final clinical step before filing for marketing authorization in Europe. The study was initiated in France in Q4 2020 and clinical centers have now also been established in Germany, Great Britain, the Netherlands and Italy. Patient enrollment has recently been completed, giving confidence to achieve the goal of implanting all PRIMAvera patients by the end of 2022, leading to an evaluation of the PRIMAvera study towards the end of 2023.
Registration:
Participation in the event is reserved for current investors only!
Please apply here register for the event, which will be held at the Pixium Vision offices in Paris.
When registering, you must…
